Table 1 Baseline patient characteristics by treatment
Variables | Abatacept n = 1496 | Other bDMARDs n = 3490 | csDMARDs n = 1520 |
|---|---|---|---|
Age, years, mean (SD) | 61.5 (12.8) | 60.9 (12.9) | 63.3 (12.9) |
Female | 85.5 | 83.6 | 80.9 |
Education, years, mean (SD) | 13.8 (2.3) | 13.9 (2.3) | 13.6 (2.4) |
White | 94.1 | 93.5 | 93.0 |
Disease duration, years, mean (SD) | 16.6 (12.2) | 16.6 (12.1) | 15.3 (13.8) |
Rheumatic Disease Comorbidity Index score (0–9), mean (SD) | 2.1 (1.7) | 2.0 (1.6) | 2.0 (1.6) |
Body mass index, kg/m2, mean (SD) | 29.0 (7.3) | 28.8 (7.1) | 29.1 (7.3) |
History of smoking | 42.9 | 45.2 | 48.2 |
Hypertension | 38.5 | 38.1 | 39.0 |
Diabetes | 12.2 | 11.9 | 13.7 |
History of cancer | 26.5 | 25.7 | 28.1 |
HAQ-DI score (0–3), mean (SD) | 1.3 (0.7) | 1.2 (0.7) | 1.1 (0.7) |
Pain score (0–10), mean (SD) | 5.6 (2.7) | 4.9 (2.8) | 4.5 (2.8) |
Patient global score (0–10), mean (SD) | 4.9 (2.5) | 4.4 (2.5) | 4.2 (2.5) |
Number of prior csDMARDs, mean (SD) | 2.9 (1.9) | 2.7 (1.8) | 2.2 (1.5) |
Number of prior bDMARDs, mean (SD) | 1.7 (1.2) | 1.0 (1.1) | 0.2 (0.6) |
 0 | 15.2 | 41.9 | 89.3 |
 1 | 34.6 | 30.3 | 6.9 |
 2–3 | 44.3 | 24.5 | 3.4 |
 ≥ 4 | 5.9 | 3.3 | 0.5 |
Concurrent methotrexate | 51.7 | 55.0 | 45.7 |
Concurrent other non-MTX csDMARDs | 21.0 | 21.0 | 37.0 |
Concurrent glucocorticoid†| 43.0 | 34.0 | 31.0 |
 < 7.5 mg/day | 63.7 | 64.9 | 65.7 |
 7.5–< 15 mg/day | 25.6 | 25.1 | 22.2 |
 ≥ 15 mg/day | 10.8 | 10.1 | 12.1 |
Concurrent NSAID | 41.3 | 42.8 | 44.5 |